Literature DB >> 15936373

The use of ventriculoperitoneal shunts for uncontrollable intracranial hypertension without ventriculomegally secondary to HIV-associated cryptococcal meningitis.

Graeme F Woodworth1, Matthew J McGirt, Michael A Williams, Daniele Rigamonti.   

Abstract

BACKGROUND: The risks associated with implanting a cerebrospinal fluid (CSF) shunt in immunocompromised patients with ongoing CSF infection have historically discouraged surgeons from implanting CSF shunts in patients with HIV and cryptococcal meningitis. However, this patient population often requires frequent lumbar punctures to manage elevated intracranial pressure (ICP) secondary to cryptococcal infection. To date, only 7 cases of ventriculoperitoneal (VP) shunting for the treatment of intracranial hypertension in patients with HIV-associated cryptococcal meningitis have been reported. Few of these reports have included outcomes more than 3 months postsurgery. It remains unclear if VP shunts are an effective long-term treatment of intracranial hypertension in this patient population. CASE DESCRIPTIONS: Two patients with HIV/AIDS (CD4 counts of 8 and 81 cells/mm(3)) presented with altered mental status, visual changes, florid cryptococcal meningitis, and elevated ICP (>500 mm CSF) without evidence of hydrocephalus on computed tomography scan. Both patients experienced rapid reversal of symptoms with external lumbar CSF drainage, and remained lumbar drain-dependent after 2 weeks of amphotericin B and flucytosine therapy. Despite evidence of unresolved cryptococcal meningitis, each patient underwent implantation of a VP shunt without complication and was discharged on lifetime fluconazole therapy. They remained asymptomatic at 12 and 16 months after surgery without evidence of shunt infection or malfunction.
CONCLUSION: Patients with intracranial hypertension and HIV-associated cryptococcal meningitis who cannot tolerate cessation of external lumbar CSF drainage or frequent lumbar punctures may be considered for VP shunt placement despite severe immunosuppression and persistent CSF cryptococcal infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936373     DOI: 10.1016/j.surneu.2004.08.069

Source DB:  PubMed          Journal:  Surg Neurol        ISSN: 0090-3019


  14 in total

1.  Evaluation and treatment of chronic meningitis.

Authors:  Kelly J Baldwin; Joseph R Zunt
Journal:  Neurohospitalist       Date:  2014-10

2.  Predictive Model for Permanent Shunting in Cryptococcal meningitis.

Authors:  Woralux Phusoongnern; Siriluck Anunnatsiri; Kittisak Sawanyawisuth; Amnat Kitkhuandee
Journal:  Am J Trop Med Hyg       Date:  2017-08-18       Impact factor: 2.345

Review 3.  Fungal infections of the CNS: treatment strategies for the immunocompromised patient.

Authors:  Katharine E Black; Lindsey R Baden
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 4.  Management of Cryptococcus gattii meningoencephalitis.

Authors:  Carlos Franco-Paredes; Tanea Womack; Teri Bohlmeyer; Brenda Sellers; Allison Hays; Kalpesh Patel; Jairo Lizarazo; Shawn R Lockhart; Wajid Siddiqui; Kieren A Marr
Journal:  Lancet Infect Dis       Date:  2014-11-26       Impact factor: 25.071

5.  An exploratory study of long-term neurocognitive outcomes following recovery from opportunistic brain infections in HIV+ adults.

Authors:  Andrew J Levine; Charles H Hinkin; Kazuhiro Ando; Gianni Santangelo; Mariana Martinez; Miguel Valdes-Sueiras; Ernestina H Saxton; Glen Mathisen; Deborah L Commins; Ardis Moe; Charles Farthing; Elyse J Singer
Journal:  J Clin Exp Neuropsychol       Date:  2008-02-08       Impact factor: 2.475

6.  Cryptococcal meningitis manifesting as a large abdominal cyst in a HIV-infected patient with a CD4 count greater than 400 cells/mm(3).

Authors:  Nancy Crum-Cianflone; April Truett; Mark R Wallace
Journal:  AIDS Patient Care STDS       Date:  2008-05       Impact factor: 5.078

7.  Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.

Authors:  John R Perfect; William E Dismukes; Francoise Dromer; David L Goldman; John R Graybill; Richard J Hamill; Thomas S Harrison; Robert A Larsen; Olivier Lortholary; Minh-Hong Nguyen; Peter G Pappas; William G Powderly; Nina Singh; Jack D Sobel; Tania C Sorrell
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

8.  Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era.

Authors:  Caroline Charlier; Françoise Dromer; Christophe Lévêque; Loïc Chartier; Yves-Sébastien Cordoliani; Arnaud Fontanet; Odile Launay; Olivier Lortholary
Journal:  PLoS One       Date:  2008-04-16       Impact factor: 3.240

Review 9.  Cryptococcal meningitis: epidemiology and therapeutic options.

Authors:  Derek J Sloan; Victoria Parris
Journal:  Clin Epidemiol       Date:  2014-05-13       Impact factor: 4.790

Review 10.  Treatment of cryptococcal meningitis in resource limited settings.

Authors:  Derek J Sloan; Martin J Dedicoat; David G Lalloo
Journal:  Curr Opin Infect Dis       Date:  2009-10       Impact factor: 4.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.